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Abstract
Mucopolysaccharidosis-I (MPS-I) is an inherited deficiency of α-L-iduronidase (IdU) that causes 
lysosomal accumulation of glycosaminoglycans (GAG) in a variety of parenchymal cell types and 
connective tissues. The fundamental link between genetic mutation and tissue GAG accumulation 
is clear, but relatively little attention has been given to the morphology or pathogenesis of 
associated lesions, particularly those affecting the vascular system. The terminal parietal branches 
of the abdominal aorta were examined from a colony of dogs homozygous (MPS-I affected) or 
heterozygous (unaffected carrier) for an IdU mutation that eliminated all enzyme activity, and in 
affected animals treated with human recombinant IdU. High resolution computed tomography 
showed that vascular wall thickenings occurred in affected animals near branch points, and 
associated with low endothelial shear stress. Histologically these asymmetric “plaques” entailed 
extensive intimal thickening with disruption of the internal elastic lamina, occluding more than 
50% of the vascular lumen in some cases. Immunohistochemistry was used to demonstrate that 
areas of sclerosis contained foamy (GAG laden) macrophages, fibroblasts and smooth muscle cells 
with loss of overlying endothelial basement membrane and claudin-5 expression. Lesions 
contained scattered cells expressing nuclear NF-κβ (p65), increased fibronectin and transforming 
growth factor β-1 signaling (with nuclear Smad3 accumulation) in comparison to unaffected 
vessels. Intimal lesion development and morphology was improved by intravenous recombinant 
enzyme treatment, particularly with immune tolerance to this exogenous protein. The progressive 
sclerotic vasculopathy of MPS-I shares some morphologic and molecular similarities to 
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atherosclerosis, including formation in areas of low shear stress near branch points, and can be 
reduced or inhibited by intravenous administration of recombinant IdU.
Keywords
atherosclerosis; mucopolysaccharidosis; pathogenesis; lysosomal storage disease; enzyme 
replacement therapy; vasculopathy
Lysosomal storage diseases are a heterogeneous group of heritable conditions associated 
with genetic mutations resulting in loss of lysosomal enzyme activity. The 
mucopolysaccharidoses are a subset of these storage disorders caused by deficiency of an 
enzyme involved in the breakdown of glycosaminoglycans (GAG). The resultant 
accumulation of GAG in parenchymal cells and connective tissues is associated with a 
progressive, debilitating, multisystem disease and typically premature death.1, 2
Mucopolysaccharidosis-I (MPS-I) is an autosomal recessive disease resulting from the 
deficiency of α-L-iduronidase (IdU) and consequent accumulation of dermatan sulfate and 
heparan sulfate GAG.2 Over 100 IdU mutations have been described in affected individuals 
and, depending on the extent to which this reduces IdU activity, clinical manifestations 
range from severe (Hurler syndrome) to mild (Scheie syndrome) or an intermediate (Hurler/
Scheie) phenotype.2 Children with Hurler disease exhibit early onset facial and skeletal 
deformities, mental retardation and may die before 10 years of age from cardiac valvular 
and/or respiratory failure. In milder forms individuals can survive into their fourth and fifth 
decades with progressive musculoskeletal problems. Effective treatment of patients with 
MPS-I currently includes administration of recombinant IdU protein to replace defective 
enzyme function.3, 4 FDA approval for this treatment in 2003 was based in part on 
preclinical testing in a canine model of MPS-I.5–7 This outbred family of dogs carries a G to 
A point mutation in the donor splice site of intron 1 that causes retention of intron 1 in the 
RNA and a premature termination codon at the exon-intron junction.8 Heterozygous carriers 
produce adequate levels of enzyme from the wild-type allele and are unaffected, as are 
human carriers. Homozygotes completely lack IdU activity and exhibit clinicopathologic 
changes similar to the intermediate form of the disease in humans.5–7
MPS-I and other forms of storage disease are rare and consequently have not been studied as 
closely as more prevalent diseases such as atherosclerosis. Most of the work in MPS-I has 
been, appropriately, directed towards therapeutic intervention and very little is known about 
its pathogenesis beyond characterization of genetic mutations and associated accumulation 
of GAG in multiple tissues and cell types. The relationship between accumulation of this 
storage material and progressive multisystem disease has only been addressed in a few 
studies.9–13 Although it may be logical to assume that intracellular accumulation of GAG 
results in cell death, this has not been established for any of the affected cell types in MPS-I 
and does not explain all pathologic changes. Abnormal lysosomal GAG accumulation 
affects GAG content and/or related biochemical structures in other intra- or extracellular 
locations and may increase or otherwise alter cell function in a cell specific or 
microenvironment-dependent manner,14 but the specific perturbations have yet to be 
determined in MPS-I.
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The vascular system is known to be affected in humans and dogs with MPS-I but, as with 
other organs, the morphology and pathogenesis of these changes has received limited study.
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–
20
 In this paper we provide new details about the morphology and potential 
contributing pathologic mechanisms involved in the development of vascular lesions in dogs 
with MPS-I, and examine the affects of recombinant IdU therapy on lesion morphology.
Materials and Methods
The canine MPS-I colony was founded at the University of Tennessee College of in 
Knoxville7 and subsequently transferred to the Harbor Research Institute, University of 
California Los Angeles Medical School, an AAALAC accredited facility. All studies were 
approved by Institutional Animal Care and Use committees. Tissues used in the current 
report were derived prospectively and retrospectively from preclinical trials, which have 
been reported in greater detail elsewhere.21–27 In short, dogs were treated intravenously 
and/or intrathecally with human recombinant IdU (BioMarin, Novato, CA) using protocols 
that included low and high IV doses (0.6 and 2 mg/kg), varying ages of treatment initiation 
(1 week to > 1 year of age) and length of treatment (weeks to > 1 yr), continuous vs periodic 
(once/week to every 3 months) therapy, and with preinduction of immune tolerance. The 
null mutation in homozygous dogs completely eliminates IdU protein expression, as is the 
case in many Hurler patients, and administration of recombinant enzyme elicits a robust 
immune response. We have found that pharmacologic induction of immune tolerance in 
these dogs enhances the beneficial effects of recombinant enzyme therapy,24 and that 
initiation of IV treatment shortly after birth also results in immune tolerance to the enzyme.
27
 Tissue samples for pathologic evaluation were obtained immediately following euthanasia 
and fixed in 10% (v/v) neutral buffered formalin. For immunohistochemical analysis the 
tissues were rinsed after 18 hours in fixative and held in 70% ethanol until they could be 
processed into paraffin for histologic sectioning. Routine hematoxylin and eosin staining 
was performed on all sections in order to compare the morphology of affected and 
unaffected vessels.
Histochemical staining
Select histologic sections were stained with a modified Movat’s pentachrome stain as 
previously described.28, 29 In these sections, elastic fibers are black, smooth muscle is red, 
collagen yellow, nuclei purple, and GAG appear blue-green. Masson trichrome stain was 
also used to highlight collagen (deep blue) and Alcian blue for acid mucopolysaccharides.
Immunohistochemistry
Immunohistochemistry (IHC) was performed by the University of Tennessee College of 
Veterinary Medicine Immunohistochemistry Laboratory as previously described.30 Primary 
antibodies (Supplementary online information) were applied for 30 min at room temperature 
and localized in situ with a horse radish peroxidase-labeled polymer (Envision+ System, 
Dako, Carpinteria, CA) and the chromogen 3,3′-diaminobenzidine. Slides incubated with 
Universal Negative Control (Dako), in place of primary antibody, served as controls. 
Positive controls included endogenous vascular proteins (α-smooth muscle actin, laminin, 
type IV collagen, claudin-5), canine granulation tissue (fibronectin, transforming growth 
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factor (TGF) β-1, Smad3, cyclooxygenase-2], or sections of canine intestine and mesenteric 
lymph node (CD18, lysozyme, proliferating cell nuclear antigen, nuclear factor (NF)-κβ 
p65, activated caspase-3).
CT Imaging
The caudal thoracic to sublumbar abdominal aorta and proximal segments of all branches 
from affected dogs were imaged using a microCAT II + SPECT imaging system (Siemens 
Preclinical Solutions, Knoxville, TN). Aortas were flushed after removal, fixed in formalin, 
and evacuated with pressurized air before imaging. The vessels and adherent surrounding 
soft tissues were imaged by CT using an X-ray voltage biased to 80 kVp with a 500 μA 
anode current, the full 90 mm × 60 mm field of view was used and the data were binned 4 × 
4. A series of 360, 1-degree projections were collected using an exposure time of 475 msec 
per projection. The data were reconstructed in real-time using an implementation of the 
Feldkamp filtered back-projection algorithm onto a 512 × 512 × 768 matrix with isotropic 
0.077 mm voxels. These data were visualized and evaluated in 3-dimensions using the 
Amira software package (Visage Imaging, Andover, MA).
RESULTS
Vascular Pathology
Most of the affected dogs in this study were between 18–24 months of age (mean 22 
months) at necropsy (Table 1) and both males and females were included. There were no 
obvious differences in vascular lesions between genders, but direct anatomic comparisons 
and quantification were not attempted. All vascular lesions were arterial; no striking 
morphologic changes were identified in the venous system. At necropsy macroscopic 
vascular changes were obvious only in the proximal aorta of affected dogs, where there was 
rugose intimal thickening and nodular plaques projecting from the wall behind semilunar 
valve leaflets (Supplemental information, Figure). Two dogs had a discrete 0.5–3 cm 
diameter, round to oval aneurysmal defect in the outer convex aspect of the aortic wall at or 
just beyond the arch (17 month old untreated; 23 month old from low dose, tolerant group). 
Smooth muscle tunics in these areas were replaced by disorganized fibrous or chondroid 
tissue with bone formation and macrophages containing hemosiderin.
Histologically the proximal aorta was characterized by severe distortion of mural 
architecture with sclerotic features as described below for smaller caliber arteries, occasional 
areas of necrosis, mineralization, or chondroid metaplasia. Smooth muscle cells of the tunica 
media in all medium to large caliber arteries were distended with clear vacuolar cytoplasm 
(glycosaminoglycan, GAG). Asymmetric areas of intimal thickening were occasionally 
found in extramural coronary and mesenteric arteries. In contrast, areas of intimal sclerosis 
were consistently and reproducibly found in transverse histologic sections from the distal 
aorta (viz. iliac branches) so we focused on this anatomic location for our studies. These 
lesions consisted of discrete to circumferential areas of asymmetric intimal thickening 
resulting in an approximate reduction of up to 60–70% of the lumen (Figures 1, 2). The 
internal elastic lamina in these areas was discontinuous with displacement of the free ends 
(Figure 3). The normal circumferential organization of the media was asymmetrically 
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distorted in association with intimal lesions by interstitial accumulations of faintly 
basophilic extracellular matrix, elastin and loss of smooth muscle cells (Figures 1, 2) with 
infrequent cartilaginous metaplasia. This disorganization of the media was particularly 
apparent in sections stained for elastin and collagen. Many of the lining endothelial cells 
contained foamy cytoplasm (GAG), but this was not restricted to areas of sclerosis (not 
shown).
The thickened tunica intima (plaque) consisted of abundant extracellular matrix and cells 
distended with finely vacuolated (foamy) cytoplasm, which was blue-green in Movat’s 
stained sections (some lysosomal content lost in histologic processing). Larger plaques 
contained small arterioles and capillaries (neovascularization). Expression of activated 
caspase-3 (as a marker of apoptosis) was very rare in areas of intimal sclerosis and was not 
found within the endothelium (not shown). A very thin rim of type IV collagen outlined 
smooth muscle cells of the media in affected and unaffected dogs (Figure 4). Laminin and 
type IV collagen were present below the endothelium lining vessels from unaffected dogs 
but these components of basal lamina were discontinuous or absent in affected vessels, 
particularly in association with intimal plaques (Figure 4). Similarly, claudin-5 was diffusely 
expressed in the endothelial lining of unaffected dog arteries and throughout most of the 
endothelium lining vessels from affected dogs, except in areas of plaque formation where it 
was absent or highly discontinuous (Figure 5). Most of the intimal mesenchymal cell types 
were identified as either fibroblasts or myofibroblasts/smooth muscle, based on elongate, 
spindled morphology, histochemical staining characteristics and expression of α-smooth 
muscle actin (Figure 2, 3). Myofibroblasts traversed regions where the internal elastic 
lamina had ruptured and were oriented perpendicular to the internal elastic lamina; when 
concentrated towards the luminal aspect of the plaque they were oriented parallel to the 
overlying endothelium. There was otherwise no pattern or organization of these cells or 
matrix within the plaques from untreated dogs. There were scattered cells expressing 
proliferating cell nuclear antigen morphologically consistent with macrophages and either 
myofibroblasts or fibroblasts within the intimal plaques (not shown), suggesting that in situ 
proliferation at least partially contributes to intimal cellularity. Although infrequent in the 
media of dogs with MPS-I, smooth muscle cells expressing proliferating cell nuclear antigen 
were much less common in the media of unaffected dogs (not shown). Macrophages were 
the other common cell type within areas of sclerosis, based on cell morphology and 
cytoplasmic or cell membrane staining for lysozyme and/or CD18 (Figure 6), respectively. 
Macrophages were scattered throughout the intimal plaques and were often clustered 
immediately below the endothelium (Figure 6) or in areas of neovascularization, most of 
them distended with foamy cytoplasm (GAG) in untreated dogs. Subendothelial foamy 
macrophages were not found in adjacent unaffected vasculature (Figure 6).
Extracellular matrix (ECM) in plaques consisted of a very loose to more densely packed 
eosinophilic fibrillar collagen separated by faintly basophilic amorphous ground substance. 
The ratio of cells to matrix varied considerably within plaques, particularly larger ones, with 
more ECM typically present towards the middle of these lesions (i.e. Figure 2). Modified 
Movat’s pentachrome and Masson trichrome histochemical staining confirmed that the 
fibrillar material was collagen (not shown). The amorphous material was often brightly 
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green-blue in Movat’s stained sections (Figures 1, 3) and also stained with Alcian blue (not 
shown), indicating the presence of glycosaminoglycans. Cytoplasmic granular staining for 
GAG was present in swollen foamy macrophages (Figure 3) and other cells containing the 
vacuolar storage material. Thick to thin short branching elastin fibrils were variably present 
within plaques, sometimes in focally dense tangles. There was consistent fragmentation and 
occasional loss of the internal elastic lamina in areas of intimal sclerosis (Figures 1, 3) as 
well as multifocal fragmentation of the external elastic laminae (not shown). 
Glycosaminoglycan-containing ground substance and collagen in some vessels extended 
from the expanded intima into or through the subjacent tunica media, separating and 
replacing the smooth muscle fibers (Figures 1, 2).
There was little to no immunostaining for TGF-β1 in vessels from unaffected dogs, but in 
affected MPS-I vessels the neointima was distinctly positive, particularly towards the lumen 
(not shown). This included the matrix and, in some instances, the cytoplasm of 
subendothelial foamy macrophages. Intracellular staining for TGF-β1 was most intense in 
the moderately distended cells compared to the markedly distended cells, where the staining 
was sparse. At the same time, nuclear expression of Smad3 was prominent in cells within 
the plaque (Figure 7).
In unaffected normal dogs, fibronectin was present in arterial subendothelial basement 
membranes, around medial smooth muscle cells, and throughout the adventitia. In vessels 
from dogs with MPS-I the most intensely stained areas corresponded to the most intensely 
labeled areas of TGF-β1 immunoreactivity, with the strongest expression in the 
subendothelial areas of intimal plaques (Figure 8). Fibronectin was predominantly found in 
the ECM but was also present in some cells. The tunica media of affected vessels had more 
staining for both TGF-β1 and fibronectin as compared to unaffected vessels, located 
primarily in areas of medial damage/remodeling near intimal plaques (not shown).
Rarely, endothelial and smooth muscle cells were immunoreactive for NF-κβ (p65) in 
control vessels from unaffected dogs. In contrast, nuclear expression increased considerably 
in the neointima of affected vessels and included some macrophages. Positive cells were 
scattered throughout the intima (Figure 9) but there were focal ‘hotspots’ with 10–15 
clustered cells expressing nuclear p65.
X-Ray Computed Tomography
In order to determine the distribution of vascular lesions along the distal aorta and its 
branches, we examined fixed tissues from several affected dogs by CT and reconstructed 
scans for 3 dimensional analyses (Supplemental information, movie). Neointimal plaques 
were found in association with arterial branches. Specifically, these were most often present 
in the aortic wall just distal (downstream) and ipsilateral to the arterial branch point(s), 
associated with asymmetric thickening of the aortic wall (corresponding to histologic lesions 
described above) and reduced luminal diameter (Figure 10). Frequently, there was also 
narrowing of the branch lumen as it exited the aorta. In areas where larger branches created 
a triad of similarly sized subsidiaries (i.e. external iliacs) the sclerotic lesions were more 
complex involving opposing lateral walls (Figure 1).
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Effects of Recombinant Enzyme Treatment
The pattern of changes in vessels from treated dogs generally followed the responses found 
in other tissues, as previously published.21–26 Adult dogs treated with IV IdU at lower doses 
(0.6 mg/kg) and not preconditioned to induce immunologic tolerance had almost no 
evidence of beneficial effects, other than a reduction in endothelial GAG storage and fewer 
subendothelial foamy macrophages. The intimal plaques and medial smooth tunics could not 
otherwise be distinguished from untreated animals. Treatment of adult dogs with the higher 
dose (2 mg/kg IV IdU) further reduced subendothelial GAG vacuolation in the plaques, 
creating a thin subendothelial rim of sclerotic tissue with less storage material in some areas, 
but the rest of the plaques and the media were otherwise unaffected by therapy. When 
animals were made tolerant to IdU through use of immunosuppressive compounds24 there 
was a distinct improvement from IV enzyme treatment with both low dose, and in particular, 
high dose regimens (Figure 11). Vessels from these dogs had less storage material within 
both plaques and the medial smooth muscle in areas without plaque formation. The intimal 
plaques were more organized with laminar organization of fibrous tissue, parallel to the 
endothelium, more compact collagen and structurally intact elastic laminae, less ECM and 
GAG (by Movat’s stain) and reduced numbers of arterioles and capillaries 
(neovascularization) and macrophages. Direct comparison of the size/thickness of these 
plaques was not feasible, but they generally appeared smaller/thinner than in treated, non-
tolerant or untreated dogs. Storage material in the medial smooth muscle in tolerant, high 
dose treated animals was still present in scattered foci (Figure 11), but often completely 
absent across the entire vessel wall. Finally, when either high (Figure 12-A) or low dose 
treatment was initiated soon after birth, all evidence of storage material was eliminated from 
the entire arterial wall in the proximal/supravalvular aorta and mural architecture, including 
the intima, was essentially the same as in normal, unaffected dogs. In contrast, proximal 
aorta from untreated littermates and any of the other treatment regimens started at an older 
age (generally > 12 months) retained storage material and degrees of sclerosis (Figure 12-
B). The distal aorta was not sampled in animals treated from birth, but complete inhibition 
of lesion development in this location (and throughout the body) can reasonably be predicted 
from responses observed in the proximal aorta.
Discussion
Vascular disease can be widespread in patients with MPS-I and, while typically not fatal, 
may contribute to clinical disease. Autopsies of MPS-I patients have shown the arterial 
narrowing to be caused by development of “Hurler plaque” within the intima and inner 
portion of the media of the large and medium-sized arteries, particularly within the heart.15–
17
 The canine model of MPS-I in our studies shares many of the same clinical and 
pathologic features as humans, including this vasculopathy. However, in contrast to the 
more extensive and diffuse sclerosis seen in coronary vessels of Hurler patients, coronary 
lesions in the dogs were more sparsely scattered and presumably associated with branch 
points (as in the distal aorta). The literature contains much less information about vascular 
lesions outside the heart in Hurler patients. Interestingly, mice with MPS-I develop 
relatively mild lesions in their proximal aorta but none of the arteriosclerotic coronary or 
peripheral arterial lesions found in affected dogs and people31 (M.F. McEntee, unpublished 
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observations). While most descriptions of cardiovascular disease in children focus on the 
cardiac valvular and coronary arterial changes, occlusive disease of the abdominal aorta and 
renal arteries can be extensive in these individuals and associated with systemic 
hypertension.16 We have found that the distal aorta and its proximal branches are also 
affected in dogs with MPS-I, although it remains to be determined whether these animals 
develop clinical hypertension. The purpose of this study was to further characterize the 
vasculopathy in dogs with MPS-I and examine the relative effects of various treatments with 
recombinant IdU.
There are distinct morphologic similarities between intimal plaques in atherosclerosis and 
MPS-I and it therefore seems logical that they also share pathogenic mechanisms, despite 
the distinct underlying metabolic disturbances. It has been shown that atherosclerotic lesions 
develop primarily in locations with low endothelial shear stress, increased turbulence and 
oscillating blood flow, associated with branches in the vascular tree.32–34 In contrast, 
regions with laminar flow and the opposite hemodynamic forces are relatively resistant to 
plaque formation. We have shown that the distal aortic lesions in dogs with MPS-I are 
localized primarily in areas subjected to the same hemodynamic factors that lead to 
atherosclerotic plaques, implicating this predisposing mechanism in MPS-I vasculopathy. 
What is not clear, however, is how GAG accumulation sensitizes these vascular tissues to 
plaque formation, as lipid imbalances and oxidative stress do in atherosclerosis. We chose to 
further characterize the nature of these lesions by looking for expression of proteins 
previously associated with atherosclerosis and/or restenosis in order to help shed some light 
on lesion morphogenesis and possible signaling pathways involved in MPS-I vascular 
disease.
Intimal plaques in dogs with MPS-I consist of a greatly expanded interstitial matrix 
containing GAG (“ground substance”), collagen and elastin. The cellular component 
consists primarily of fibroblasts and myofibroblasts (or smooth muscle cells), responsible 
for much of the matrix deposition. These cells, which were often themselves distended with 
GAG storage material, could have either migrated into the intima through fracture sites in 
the underlying internal elastic lamina, as dedifferentiated smooth muscle, or perhaps through 
the overlying endothelial layer from circulating mesenchymal stem cells,35 with subsequent 
local replication. In either case the asymmetric and localized distribution of the plaques 
within the vasculature implicates endothelium and/or internal elastic lamina as primary 
targets of hemodynamic forces in early Hurler plaque formation. Endothelial cells subjected 
to the hemodynamic forces typically found around branch points have a markedly altered 
gene expression profile and phenotype.34, 36 We have shown that endothelial basal lamina 
components and the adhesion protein claudin-5 are down regulated in areas of plaque 
formation, presumably when endothelium in these areas is subjected to reduced shear stress 
and other atherogenic hemodynamic forces. These effects in areas of plaque formation 
would increase endothelial permeability and egress of circulating cells. In fact, 
macrophages, many laden with GAG, were common immediately below the endothelium in 
areas of neointimal plaque formation. These macrophages might then contribute to lysis of 
the internal elastic lamina with release of various degradative enzymes (e.g. membrane 
metalloproteinases) and lesion progression. Although plausible, the phenotype and biologic 
activity of macrophages in this disease has not been adequately examined. We have shown, 
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however, that at least some of the intralesional macrophages in the canine Hurler plaques 
exhibit activated NF-κβ signaling and/or upregulation of TGF-β1 expression. These changes 
no doubt contribute to a phlogistic tone as well as expansion and remodeling of connective 
tissues with plaque growth, as occurs in atherosclerosis. Surprisingly, we very rarely 
encountered cyclooxygenase-2 expression in the canine vascular lesions (not shown), 
distinguishing them from atherosclerosis. Although endothelial cell apoptosis was not found 
in sections stained for activated caspase-3, this certainly does not rule out the potential for 
low rates of cell death particularly as these would rapidly detach into the blood. It was clear 
that endothelial cells in this area of the vasculature were laden with GAG in MPS-I affected 
dogs, and damage or loss of endothelium through apoptosis, in addition to altered responses 
to normal hemodynamic forces, could contribute to plaque initiation and propagation.
TGF-β1 and fibronectin are integral in many physiologic and pathophysiologic processes 
and their expression was distinctly increased in the matrix of canine intimal plaques and, in 
particular, just below the endothelium. TGF-β1 is a multifunctional cytokine that exerts its 
affects in a both autocrine and paracrine manner to regulate cell proliferation, 
differentiation, wound repair and tissue remodeling. It promotes net matrix deposition by 
increasing the expression of specific ECM components such as fibronectin, collagen, 
dermatan and heparan sulfate proteoglycans, and inhibitors of the ECM proteases, such as 
tissue inhibitors of matrix metalloproteinases. TGF-β1 simultaneously down-regulates 
proteases which degrade matrix components, and the net effect is connective tissue 
expansion.37–39 Fibronectin, in turn, can cause smooth muscle activation and migration, and 
is chemotactic for macrophages.40 The TGF-β-fibronectin system plays a vital role in the 
characteristic changes of the vascular smooth muscle cells during transition from a structural 
to a synthetic phenotype, as occurs with atherosclerotic plaque formation; by analogy it 
seems likely this stimulus is also involved in the appearance of α-smooth muscle actin 
positive myofibroblasts and matrix deposition in Hurler plaques. TGF-β1 directly or 
indirectly induces fibronectin production, which may involve activation of NF-κB through 
the JNK pathway.41 NF-κβ transcriptional activation was demonstrated in the MPS-I 
plaques with intranuclear migration of p65 (REL-A) and is central in all toll-like receptor 
signaling pathways. Interestingly, toll-like receptor-4 has recently been shown to play a role 
in MPS disease expression.11, 12
The fact that MPS-I sensitizes dogs to intimal arterial disruption and sclerosis associated 
with hemodynamic stressors that are also associated with atherosclerotic plaque formation is 
intriguing, but much more work will be required to determine the underlying mechanisms 
and the pathogenic relationship between intracellular storage material and the morphologic 
changes noted above. The lysosome is now recognized as important in diverse cellular 
functions, in addition to degradation and recycling of intra- and extracellular materials.14 
Accumulation of dermatan and heparan sulfate GAG within this compartment in 
endothelium, fibroblasts, macrophages and myofibroblasts of MPS-I patients must be 
responsible for the subsequent tissue changes either through cytotoxic effects and/or altered 
cell function/signaling, dependent on the degree of storage and microenvironmental cell/
tissue context. Our results strongly suggest that this manifests as a localized phenomenon in 
the vasculature of MPS-I dogs in response to normal hemodynamic forces that are also 
responsible for atherogenesis. Reduction of this storage material in the vasculature with 
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recombinant enzyme therapy clearly mitigates the vasculopathy, particularly in the context 
of immune tolerance achieved either through administration of the enzyme at an early age or 
use of immunosuppressive drugs. We attribute the role of immune tolerance in ERT efficacy 
to be enhanced delivery of the enzyme, and not a result of drug-induced 
immunosuppression, because: 1) specific antibodies against the enzyme inhibit uptake in 
vitro; 2) the immune suppressive drugs were administered for a limited time (60 days); and 
3) animals treated with an abbreviated regimen (21–45 days) of immunosuppressive drugs 
that failed to induce tolerance exhibited similar tissue ERT efficacy as that observed in non-
tolerant dogs that had not received these drugs.24 Thus, administration of 
immunosuppressive drugs without induction of tolerance does not improve efficacy of ERT. 
We have shown in these studies that early initiation of ERT may prevent arterial 
vasculopathy associated with MPS-I, and have reported elsewhere that the same is true for 
other refractory tissues such as the atrioventricular valve.27 Whether longer term therapy 
initiated in older animals would eventually result in complete remodeling and regression of 
these plaques, as suggested for atherosclerosis,42 remains to be determined. Further 
investigation of the pathogenic role abnormal GAG accumulation plays in altering the 
normal cell-cell, cell-matrix interactions in MPS-I (and other storage diseases) is warranted 
in order to develop adjunct therapies that complement use of recombinant IdU.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Transverse histologic section from an untreated dog with MPS-I through distal aorta 
(central) just beyond branch points of external iliac arteries (left and right). Asymmetric 
areas of intimal sclerosis containing GAG (blue-green) infringe on vessel lumens and the 
normal smooth muscle (red) of the vessel is disrupted. Vena cava is below the arteries 
(Movat’s modified pentachrome).
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Figure 2. 
Intimal plaque replacing >50% of an arterial lumen from an untreated MPS-I dog contains 
smooth muscle and/or myofibroblasts (brown stain) with some loss of normal muscle 
structure in the media (asterisk; α-smooth muscle actin IHC).
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Figure 3. 
Plaque in an untreated MPS-I dog showing disruption of internal elastic lamina (black). 
Plaque matrix with GAG (blue-green) separating smooth muscle cells (red), containing 
cytoplasmic storage material (vacuolation). Smaller foamy macrophages, also with 
cytoplasmic GAG storage, are scattered throughout and clustered in this image (arrow) 
around a free end of the internal elastic lamina (Movat’s modified pentachrome).
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Figure 4. 
Arterial wall (to left) and intimal plaque (arrows = internal elastic lamina) from an untreated 
MPS-I affected dog stained for type IV collagen, which encircles smooth muscle of media 
but is absent under the endothelium lining the plaque (type IV collagen IHC stain).
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Figure 5. 
Endothelial claudin-5 expression in an untreated MPS-I affected dog is almost completely 
lost over intimal plaques (arrow), in comparison to adjacent arterial wall, were no plaque is 
present (insets; claudin-5 IHC stain).
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Figure 6. 
Macrophages in small/early sclerotic plaque (arrows) and larger plaque (inset) in vessels 
from untreated dogs. Macrophages were not present in arterial walls outside plaques and 
were often clustered immediately below the endothelium (inset arrows) of the affected 
vessel (CD18 IHC stain).
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Figure 7. 
Intimal plaque (endothelium at top) from an untreated dog with MPS-I has nuclear Smad3 
localization (brown) in scattered cells morphologically consistent with fibroblasts/
myofibroblasts and macrophages, indicating TGF-β signaling (Smad3 IHC stain).
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Figure 8. 
Fibronectin expression in an intimal plaque from an untreated dog with MPS-I contains 
more abundant fibronectin staining than the adjacent media, with rapid decreases at the 
internal elastic lamina. The densest accumulations were subjacent to the endothelium (to 
right of image). (Fibronectin IHC stain).
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Figure 9. 
Intranuclear localization of p65 indicating activation of NF-κB signaling in scattered cells 
within the intimal plaque of an untreated dog with MPS-I (p65 IHC stain).
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Figure 10. 
Reconstruction of sublumbar aortic microCT scan from a non-tolerant dog with MPS-I that 
had received low doses of IdU. Areas of intimal plaque formation (asterisks) are localized 
just beyond arterial branch points and taper distally along the aortic wall, with some 
thickening at the os of these branches and luminal narrowing. In contrast, vessels from 
normal animals are cylindrical structures with smooth interior surfaces, constant luminal 
diameters and have a uniform circumferential wall thickness.
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Figure 11. 
Affected large caliber artery from MPS-I affected dog made tolerant to IdU and treated 
weekly with high doses of recombinant enzyme. The intimal plaque is more organized with 
complete absence of storage material (arrow = internal elastic lamina). Intracellular GAG 
vacuolization has been almost completely eliminated in the adjacent media (hematoxylin 
and eosin stain).
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Figure 12. 
In comparison to animals receiving any form of treatment at an older age (A; high dose IdU 
without tolerance. Dotted line = internal elastic lamina), the proximal (supravalvular) aorta 
from dogs treated from birth (B; high dose IdU) completely lacked any evidence of 
intracellular storage material in the media (inserts) or intimal plaque formation (hematoxylin 
and eosin stain).
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Table 1
Ages of MPS-I affected dogs and non-affected carriers (normal control) at necropsy. All ages in months.
Group Number Mean Age Age Range
Untreated 4 16.5 13–18
Unaffected Carriers 2 - 15, 78
Low Dose, Non-tolerant 11 28.7 13–40
Low Dose, Tolerant 9 18.6 13–25
Low Dose, From Birth 2 - 17, 18
High Dose, Non-tolerant 6 17.5 13–31
High Dose, Tolerant 3 18 17–20
High Dose, From Birth 2 - 13, 13
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